ChemoCentryx, Inc. (CCXI) financial statements (2021 and earlier)

Company profile

Business Address 850 MAUDE AVENUE
MOUNTAIN VIEW, CA 94043
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments173171199222177173182
Cash and cash equivalents39363979282469
Short-term investments134135161143149149113
Receivables0  0200
Other undisclosed current assets1234233
Total current assets:174173202227181176185
Noncurrent Assets
Operating lease, right-of-use asset22  
Property, plant and equipment2211222
Long-term investments and receivables29352412 1320
Long-term investments29352412 1320
Other noncurrent assets1100000
Other undisclosed noncurrent assets  21   
Total noncurrent assets:3540281521522
TOTAL ASSETS:209212230241183191207
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities21191614141212
Accounts payable2111111
Accrued liabilities20181513131211
Deferred revenue3837  
Other undisclosed current liabilities  4152504957
Total current liabilities:59555766646169
Noncurrent Liabilities
Long-term debt and lease obligation20202020201515
Long-term debt, excluding current maturities20202020201515
Liabilities, other than long-term debt647520000
Deferred revenue6374  
Other liabilities1120000
Other undisclosed noncurrent liabilities  8074849394
Total noncurrent liabilities:849510295104108109
Total liabilities:143150158161169169178
Stockholders' equity
Stockholders' equity attributable to parent66627181152129
Common stock0000000
Additional paid in capital496476473467389385382
Accumulated other comprehensive income (loss)000(0)(0)(0)(0)
Accumulated deficit(430)(414)(402)(386)(374)(364)(353)
Stockholders' equity note, subscriptions receivable(0)(0)(0)(0)(0)(0)(0)
Total stockholders' equity:66627181152129
TOTAL LIABILITIES AND EQUITY:209212230241183191207

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenue from related parties 1178   
Gross profit:1011789915
Operating expenses(26)(24)(23)(21)(21)(21)(23)
Operating loss:(16)(14)(16)(13)(11)(12)(7)
Nonoperating income1111111
Investment income, nonoperating1111111
Interest and debt expense(1)(1)(1)(1)(0)(0)(0)
Loss before gain (loss) on sale of properties:(16)(13)(16)(12)(11)(11)(7)
Other undisclosed net income1  10  
Net loss:(16)(13)(16)(12)(11)(11)(7)
Other undisclosed net income attributable to parent 11  00
Net loss available to common stockholders, diluted:(16)(13)(15)(12)(11)(11)(7)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(16)(13)(16)(12)(11)(11)(7)
Comprehensive loss:(16)(13)(16)(12)(11)(11)(7)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)110(0)00
Comprehensive loss, net of tax, attributable to parent:(16)(13)(15)(12)(11)(11)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: